- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2018
- Public Summary Document (PSD) July 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2018 PBAC Meeting - Word
Nivolumab (malignant melanoma) – July 2018
Nivolumab (malignant melanoma): Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection co
Last updated
9 November 2018